Compare CIEN & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CIEN | HALO |
|---|---|---|
| Founded | 1992 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.7B | 12.0B |
| IPO Year | 1996 | 2001 |
| Metric | CIEN | HALO |
|---|---|---|
| Price | $346.33 | $112.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 11 |
| Target Price | ★ $382.69 | $78.64 |
| AVG Volume (30 Days) | ★ 2.1M | 1.3M |
| Earning Date | 06-04-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.55 | N/A |
| EPS | ★ 4.34 | 3.11 |
| Revenue | ★ $4,769,507,000.00 | $151,862,000.00 |
| Revenue This Year | $30.83 | $28.24 |
| Revenue Next Year | $19.87 | $12.56 |
| P/E Ratio | $79.38 | ★ $35.27 |
| Revenue Growth | ★ 18.79 | N/A |
| 52 Week Low | $133.88 | $61.23 |
| 52 Week High | $637.51 | $111.15 |
| Indicator | CIEN | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 44.13 | 70.03 |
| Support Level | $317.45 | $103.47 |
| Resistance Level | $365.90 | N/A |
| Average True Range (ATR) | 20.30 | 2.75 |
| MACD | 1.05 | -0.63 |
| Stochastic Oscillator | 43.80 | 98.74 |
Ciena is a leader in high-speed optical connectivity, providing systems, components, and automation software for telecom providers and enterprises, such as data centers, to enable long-distance connectivity. The company operates through four primary business segments: networking platforms, platform software and services, Blue Planet automation software, and global services. While telecom carriers remain important customers, cloud providers and hyperscalers now drive a significant portion of the business. To meet the demands of AI data centers, customers are adopting Ciena's WaveLogic 6 platform, the first to support 1.6 terabits-per-second capacity.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.